| answer text |
<p>We have not made a specific assessment of the potential impact of changes to 2019
Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) payment percentages
on late-stage clinical trials and access to new medicines. An assessment relevant
to these issues was published in December 2022 on the impact of changes to payment
percentages in the associated Statutory Scheme for Branded Medicines.</p><p>Changes
to the VPAS payment percentages reflect the scheme working as intended to adjust for
increased sales of branded medicines to the National Health Service and are below
the rate projected when the Scheme was agreed with industry in 2018.</p><p>The NHS
has delivered a record number of access agreements since VPAS was agreed including
many world and European-first agreements. The NHS has delivered world-leading uptake
of some of the most important cancer and rare disease drugs, while also agreeing deals
for a number of new cell and gene therapies.</p>
|
 |
